Core Viewpoint - Baiaosaitu (688796) has successfully listed on the Sci-Tech Innovation Board, with its stock opening up 117.4% at 58 CNY per share [1] Company Overview - Baiaosaitu is an innovative drug preclinical CRO and biotechnology company, primarily providing antibody drug discovery and preclinical research services [1] - The company's services include the sale of innovative model animals, preclinical pharmacology and efficacy evaluation services, and antibody development [1] Stock Listing Details - Baiaosaitu previously issued H-shares in September 2022 and is listed on the Hong Kong Stock Exchange [1] - Following the A-share public offering, the company will have its stock listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange, with 75.21% of shares circulating in A-shares and 24.79% in H-shares [1] - The proportion of circulating shares in A-shares is higher than that in H-shares [1]

Core Viewpoint - BaiO Saite (688796) is set to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, with an issue price of 26.68 yuan per share [2]. Company Overview - BaiO Saite is an innovative drug preclinical CRO and biotechnology company, primarily engaged in providing antibody drug discovery and preclinical research services for innovative drug enterprises [2]. - The company's specific services include the sale of innovative model animals, preclinical pharmacology and efficacy evaluation services, and antibody development [2].